Nootropics+

What GHK-Cu actually does — and what the research still doesn't show

Copper peptides get sold with a lot of confidence. Most of it is borrowed from fifty years of laboratory work that has never been repeated in a large human trial. Here is what the evidence supports, what it doesn't, and why the difference matters when you're choosing a cream.

What GHK-Cu is

GHK-Cu is a tripeptide — three amino acids, glycine-histidine-lysine — bound to a copper ion. It occurs naturally in human plasma and saliva, and its concentration in the body falls with age. It was first isolated from human albumin in the 1970s by Loren Pickart, and has been studied continuously since.

It is not a new or exotic compound. It is one of the most heavily characterised regenerative peptides in the published literature, which is exactly why it attracts both serious research and unserious marketing.

The mechanism is well mapped

At the cellular level the evidence is strong and consistent across decades.

GHK-Cu acts on gene expression rather than on a single receptor. In a 2018 review of the gene-expression data, Pickart and Margolina reported that the peptide shifted the expression of thousands of measured human genes by 50% or more, and that the pattern of change moved tissue from a diseased state toward a more normal one (Pickart & Margolina, International Journal of Molecular Sciences, 2018).

The downstream effects repeatedly reported in laboratory and animal work:

None of that is in serious dispute. If you want a peptide with a genuinely deep mechanistic literature, this is the one.

The human evidence is thin, and the literature says so

Here is the part marketing pages skip. A 2026 systematic review, run to PRISMA standards across PubMed, ScienceDirect and the Cochrane CENTRAL registry, screened 1,247 records and retained 64 for qualitative synthesis. Its own summary of the human evidence:

"The clinical literature in humans remains thin and fragmented: most randomized trials are small, conducted on facial cosmetic creams, and rarely paired with delivery technologies capable of reliably crossing the stratum corneum."

The review also notes that much of the clinical literature shaping product development comes from a small number of facial-cream studies conducted in the early 2000s, which have not been replicated in larger or more rigorous modern trials — and that no adequately powered, registered human trial of the peptide with enhanced delivery has been published.

The strongest single human result cited in that review involved copper peptides combined with microneedling for acne scars: a 50.3% improvement on the Goodman & Baron scale in the combined group versus 26.3% with microneedling alone. That is a real signal. It is also a small study, and it does not isolate the peptide from the needling.

So: biologically active, yes, convincingly. Clinically proven in a large topical trial, no. Anyone telling you otherwise is overselling.

The actual problem is delivery, not concentration

This is the part that should change how you read a label.

GHK-Cu is hydrophilic and carries a charge. The outer layer of skin, the stratum corneum, is built to keep water-soluble, charged molecules out. That is its job. A cream can contain a perfectly dosed peptide and deliver very little of it to where it matters.

Which means the number on the front of the jar — the one every brand fights over — may be the least informative thing about the product. A 4% product that sits on the surface and a 0.1% product that penetrates are not meaningfully compared by their percentages.

It also explains a labelling habit worth knowing about. Many "4% copper peptide" creams are quoting the concentration of the solution the manufacturer buys, not the peptide content of the finished cream. A 4% solution used at 2.5% in a formula delivers 0.1% Copper Tripeptide-1. Both numbers are true. Only one is on the label, and it isn't the one describing what's in the jar.

What this means if you're buying a cream

What we claim, and what we don't

Our cream's peptide content is stated on the batch COA that ships with each lot, not printed on the jar. A jar can't be corrected once it is filled. A certificate can.

We claim cosmetic effects: skin that looks smoother, more even and more supple with consistent use over weeks. We don't claim to repair tissue, treat a condition, or reverse ageing, because the human evidence doesn't support those statements at this level of delivery — and because they would make this a drug, not a cosmetic.

That's a smaller promise than most brands make. It's the one we can support.

References

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520.
  2. Systematic review of the mechanisms and therapeutic applications of GHK-Cu, 2005–2026. PRISMA framework; PubMed, Elsevier ScienceDirect, Cochrane CENTRAL; 1,247 records screened, 64 retained. PMC13604022.

A note on this page

This article summarises published research. It is not medical advice, and it is not a claim that any product prevents, treats or cures a condition. Cosmetic products described on this site are not intended to diagnose, treat, cure or prevent any disease.

More on copper peptides and what the evidence actually supports: the journal index. Or see CU29.